- Home
- MVO vs TNYA Comparison
MVO vs TNYA Comparison
Compare MVO & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVO
- TNYA
- Stock Information
- Founded
- MVO 2006
- TNYA 2016
- Country
- MVO United States
- TNYA United States
- Employees
- MVO N/A
- TNYA N/A
- Industry
- MVO Oil & Gas Production
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- MVO Energy
- TNYA Health Care
- Exchange
- MVO Nasdaq
- TNYA Nasdaq
- Market Cap
- MVO 66.6M
- TNYA 73.8M
- IPO Year
- MVO N/A
- TNYA 2021
- Fundamental
- Price
- MVO $5.80
- TNYA $0.61
- Analyst Decision
- MVO
- TNYA Strong Buy
- Analyst Count
- MVO 0
- TNYA 5
- Target Price
- MVO N/A
- TNYA $8.60
- AVG Volume (30 Days)
- MVO 55.1K
- TNYA 3.0M
- Earning Date
- MVO 01-01-0001
- TNYA 08-07-2025
- Dividend Yield
- MVO 17.46%
- TNYA N/A
- EPS Growth
- MVO N/A
- TNYA N/A
- EPS
- MVO 1.46
- TNYA N/A
- Revenue
- MVO N/A
- TNYA N/A
- Revenue This Year
- MVO N/A
- TNYA N/A
- Revenue Next Year
- MVO N/A
- TNYA N/A
- P/E Ratio
- MVO $7.29
- TNYA N/A
- Revenue Growth
- MVO N/A
- TNYA N/A
- 52 Week Low
- MVO $8.85
- TNYA $0.36
- 52 Week High
- MVO $13.95
- TNYA $4.06
- Technical
- Relative Strength Index (RSI)
- MVO 48.04
- TNYA 53.87
- Support Level
- MVO $5.55
- TNYA $0.54
- Resistance Level
- MVO $5.97
- TNYA $0.70
- Average True Range (ATR)
- MVO 0.23
- TNYA 0.06
- MACD
- MVO -0.01
- TNYA 0.00
- Stochastic Oscillator
- MVO 28.17
- TNYA 34.57
About MVO MV Oil Trust Units of Beneficial Interests
MV Oil Trust is a statutory trust. Its underlying properties consist of MV Partners, LLC's (MV Partners) net interests in all of its oil and natural gas properties, which are located in the Mid-Continent region in the States of Kansas and Colorado. These properties include producing oil and gas wells.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.